1 **TITLE**

2 HIV-1 5'-Leader Mutations in Plasma Viruses Before and After the Development of Reverse Transcriptase

3 Inhibitor-Resistance Mutations

5 **SHORT TITLE**

6 HIV-1 5'-Leader Plasma Virus Sequences

7
8
AUTHORS

Janin Nouhin[1]*, Philip Tzou[2]*, Soo-Yon Rhee[2]*, Malaya K. Sahoo[3], Benjamin A. Pinsky[4], Miri A. Krupkin[5],

Joseph D. Puglisi[5], Elisabetta V. Puglisi[5], Robert W. Shafer[2]

*Each of these authors contributed equally to the work

AFFILIATIONS

[1]Division of Infectious Diseases, Stanford University, Stanford, CA, USA and Virology Unit, Institut

Pasteur du Cambodge, Pasteur Network, Phnom Penh, Cambodia; [2]Division of Infectious Diseases,

Stanford University, Stanford, CA, USA; [3]Department of Pathology, Stanford University, Stanford, CA,

USA; [4]Division of Infectious Diseases, Department of Medicine, Stanford University, Stanford, CA, USA;

Department of Pathology, Stanford University, Stanford, CA, USA; [5]Department of Structural Biology,

Stanford University School of Medicine, Stanford, CA, USA.

Abstract word count: 300

Text word count: 2,897

ABSTRACT

Background: HIV-1 RT initiation depends on interaction between viral 5'-leader RNA, RT, and host

tRNA3$_{Lys}$. We therefore sought to identify co-evolutionary changes between the 5'-leader and RT in

viruses developing RT-inhibitor resistance mutations. **Methods:** We sequenced 5'-leader positions 37-

356 of paired plasma virus samples from 29 individuals developing the NRTI-resistance mutation M184V,

19 developing an NNRTI-resistance mutation, and 32 untreated controls. 5'-leader variants were defined

as positions where ≥20% of NGS reads differed from the HXB2 sequence. Emergent mutations were

defined as nucleotides undergoing ≥4-fold change in proportion between baseline and follow-up.

Mixtures were defined as positions containing ≥2 nucleotides each present in ≥20% of NGS reads.

Results: Among 80 baseline sequences, 87 positions (27.2%) contained a variant; 52 contained a

mixture. Position 201 was the only position more likely to develop a mutation in the M184V (9/29 vs.

0/32; p=0.0006) or NNRTI-resistance (4/19 vs. 0/32; p=0.02; Fisher's Exact Test) groups than the control

group. Mixtures at positions 200 and 201 occurred in 45.0% and 28.8%, respectively, of baseline

samples. Because of the high proportion of mixtures at these positions, we analyzed 5'-leader mixture

frequencies in two additional datasets: five publications reporting 294 dideoxyterminator clonal

GenBank sequences from 42 individuals and six NCBI BioProjects reporting NGS datasets from 295

individuals. These analyses demonstrated position 200 and 201 mixtures at proportions similar to those

in our samples and at frequencies several times higher than at all other 5'-leader positions. **Conclusions:**

Although we did not convincingly document co-evolutionary changes between RT and 5'-leader

sequences, we identified a novel phenomenon, wherein positions 200 and 201, immediately

downstream of the HIV-1 primer binding site exhibited an extraordinarily high likelihood of containing a

nucleotide mixture. Possible explanations for the high mixture rates are that these positions are

particularly error-prone or provide a viral fitness advantage.

INTRODUCTION

The first 356 nucleotides of the RNA genome, the 5'-leader extends from the start of the

transactivating response (TAR) element at HXB2 position 455 in the proviral DNA sequence to HXB2

position 810 (1). The 5'-leader exists as a mixture of monomeric and dimeric species and its secondary

structure has been studied using biochemical, NMR(2) , and cryo-EM (3,4) studies. The 5'-leader has

multiple functional units including TAR, which is required for initiating transcription; several RNA

elements required for RT initiation including the invariant primer binding site (PBS); and several

downstream elements responsible for viral splicing, dimerization, and packaging.

One rate-limiting step in retroviral replication is the initiation of reverse transcription. This

process requires a three-way interaction between the viral RNA genome, the reverse transcriptase (RT)

enzyme, and $tRNA3_{Lys}$. During this process, RT binds to the viral RNA-$tRNA3_{Lys}$ duplex forming the reverse

transcription initiation complex (3). RT initiation represents a bottleneck to HIV-1 replication as

evidenced by an approximately 100-3000-fold reduced rate of nucleotide incorporation during initiation

compared with elongation and by the much slower synthesis of the first 200 HIV-1 nucleotides

compared to the remaining nucleotides of proviral DNA (5).

We hypothesized that during RT initiation there may be an interplay between changes in RT and

the 5-leader viral RNA. In particular, we questioned whether the 5'-leader would evolve to adapt to the

development of drug-resistance mutations (DRMs) in the RT enzyme. Therefore, we sequenced the 5'-

leader region of plasma virus samples obtained from individuals before and after the development of

the most common nucleoside RT inhibitor (NRTI) mutation M184V or a non-nucleoside RT inhibitor

(NNRTI)-resistance mutation.

METHODS

Individuals and samples

We identified individuals undergoing two or more genotypic resistance tests at different times

for clinical purposes who had cryopreserved remnant plasma samples meeting one of the following

criteria: (1) Had a baseline sample lacking the 3TC/FTC-resistance mutation M184V/I and a follow-up

sample containing M184V ("M184V group"); (2) Had a baseline sample lacking an NNRTI-resistance

mutation and a follow-up sample containing an NNRTI-resistance mutation ("NNRTI group"); and (3) Had

two or more samples at different times lacking M184V/I or an NNRTI resistance mutation ("Control

group"). Individuals meeting the first criteria were required to not have a history of a sample with

M184V/I and individuals meeting the second criteria were required to not have a history of a sample

with an NNRTI-resistance mutation. To be eligible for next-generation sequencing (NGS), samples were

required to have a plasma HIV-1 RNA level ≥10,000 copies/ml.

The remnant plasma samples used in this study were obtained between the years 2000 and

2017. The Stanford University Institutional Review Board approved this study under protocol 6633,

entitled "Human Immunodeficiency Virus Quasispecies During Antiviral Therapy". The approval included

a waiver of consent because the study used anonymized de-identified data and remnant plasma

samples. The authors did not access data enabling them to identify individual participants. The samples

were sequenced and the data were collected for research purposes between July 2019 and January

2020 and between September 2020 and January 2021.

Sequencing protocol

Total nucleic acids were extracted from 200 uL of plasma using the EZ1 Virus Mini Kit V2.0 on

the automated EZ1 advanced XL (both from Qiagen), according to manufacturer's instructions. Nucleic

acids were eluted in 60uL of AVE buffer and the 5'-leader region was amplified using the following

amplification strategy. First, one-step RT-PCR (SuperScript III) was performed using HIV-1 specific

primers with 5' tags to enable sample indexing during a second PCR. The PCR primers were

complementary to HXB2 positions 469-490 (5'-GACCAGATCTGAGCCTGGGAGC) and 863-844 (5'-

CCCCCTGGCCTTAACCGAAT). The resulting amplicon encompassed HXB2 positions 491-843 which

included the 5'-leader positions 37-356. A second PCR was then performed to multiplex samples with

dual indexes using NEBNext Multiplex Oligos for Illumina (New England Biolabs). Library quality and

concentration were measured using the Agilent DNA 1000 kit (Agilent Technologies). The PCR products

showing non-specific peaks were purified again using E-gel SizeSelect II Agarose Gel, 2% (Invitrogen)

according to manufacturer's instructions. Amplicons were pooled at equimolar concentration and

purified using AMPure XP beads (Beckman Coulter). The library was spiked with 12.5% PhiX and loaded

onto an Illumina MiSeq v2 Cartridge at 8 pM and was sequenced using 2 x 250 bp runs.

Sequence analysis pipeline

The Fastp program was applied to each FASTQ file to trim adapters, remove regions with low

phred scores, and stich paired reads (6). Trimmed sequence reads were aligned to the HXB2 5'-leader

sequence using Minimap2 and the alignments were saved in Sequence Alignment Map (SAM) text files

(7). Samtools were used to convert the resulting SAM text files into binary BAM files and BAI index files

(8). PySam was used to read each BAM file to construct nucleotide frequency files containing the

proportions of each nucleotide and indel at each 5'-leader position. Paired samples for which both

baseline and follow-up contained a read depth of ≥200 at all 5'-leader positions between 37 and 356

were retained for analysis.

We then created consensus sequences using IUPAC codes, whenever one or more nucleotide

was present in ≥20% of sequence reads at the same position. These sequences were submitted to

GenBank (accession numbers: OQ814268-OQ814427) and used to construct a neighbor-joining

phylogenetic tree. The phylogenetic tree employed a weighted distance matrix, which utilized the

Jaccard distance to account for the overlap among nucleotides when more than one nucleotide was

present at the same position. The 160 unedited fastq files were submitted to the NCBI Sequence Read

Archive (BioProject PRJNA954829).

For each baseline and follow-up sequence, we reported all nucleotides, insertions, and deletions

present in ≥20% of sequence reads. Mutational changes between baseline and follow-up were defined

as nucleotides or indels for which the proportion of reads containing them changed by ≥4-fold and that

were present at follow-up in ≥20% of reads. This requirement therefore occasionally necessitated noting

which nucleotides and indels in the baseline sequence were present between 5% and 20% of reads.

<u>Analysis of previously published HIV-1 group M 5'-leader sequences</u>

<u>One-per-person sequence set:</u> We searched the June 2021 version of the Los Alamos National

Laboratory HIV Sequence Database (LANL) for non-problematic HIV-1 5'-leader group M sequences with

a minimal length of 250 nucleotides. Sequences were grouped into submission sets according to the

GenBank "Title" and "Author" fields. Submission sets that were not linked to a PubMed reference or

that contained sequences from fewer than five persons were excluded from analysis. When multiple

sequences were available for the same person, we randomly selected one sequence for analysis. The

search yielded 85 studies containing 1,417 one-per-person 5'-leader sequences.

Each sequence was first aligned to the HXB2 reference 5'-leader sequence using the Smith-

Waterman algorithm included in the European Molecular Biology Open Software Suite (EMBOSS)

package (9). Next a multiple sequence alignment of the 5'-leader regions was performed using MAFFT

with a set of 157 pre-aligned subtype reference sequences from LANL as a seed alignment using the

option for adding unaligned sequences (10). The alignment was then manually adjusted to increase the

consistency of indel placement. For each 5'-leader position we determined the frequency of each

nucleotide and each indel.

Clonal sequences set: Among the 85 publications reporting HIV-1 group M 5'-leader sequences

from ≥5 persons, we identified five publications that reported an average of at least three clones per

person with active virus replications (11–15). Four publications reporting at least three clones per

person were excluded because the clones were from proviral DNA samples from persons with virological

suppression and they contained large numbers of deletions.

NGS set: We reviewed the NCBI Sequence Read Archive (SRA) to identify published studies in

which NGS encompassed the 5'-leader in at least five persons. We analyzed the sequences from each of

these studies using the NGS pipeline described above ("Sequence analysis section"). Overall, there were

246 SRA BioProjects including 63 containing 5'-leader sequences as determined by our sequence

analysis pipeline. Six publications contained sequences from 295 persons (between 8 and 105 persons

per publication) (16–21).

RESULTS

Individuals and samples

Samples before and after ART were available for 29 individuals who developed M184V and for

19 individuals who developed an NNRTI-resistance mutations including K103N (n=13), Y181C (n=5), and

G190A (n=1). Samples from two time points were available from 32 control individuals who were ART-

naïve and who did not develop any RTI-resistance mutations. Table 1 summarizes the demographics,

ART histories, and baseline laboratory values for each group of individuals. Among the 29 individuals in

the M184V group, 19 were NRTI-naïve at the time of the first sample. Nine had previously received 3TC

or FTC but never developed M184V; one had received NRTIs other than 3TC or FTC. Among the 19

individuals in the NNRTI-resistance group, 16 were NNRTI-naïve and three had previously received an

NNRTI   but   never   developed   NNRTI   resistance.

Table 1. Description of the 80 Individuals Undergoing Baseline and Follow-Up HIV-1 5'-Leader Sequencing

	Control Group (n=33)	M184V Group (n=29)	NNRTI-Resistance Group (n=19)	P value[1] Control vs. M184V	Control vs. NNRTI	M184V vs. NNRTI
Sex	30 male / 2 female	24 male / 5 female	16 male / 3 female	NS	NS	NS
Age (IQR)	39 (26.8-51)	42 (33-47)	41 (33-48)	NS	NS	NS
Year (IQR)	2011 (2006-2014)	2001 (2001-2004)	2004 (2001-2010)	<0.001	0.003	NS
Baseline ART history[2]	Naïve: 32	NRTI-naïve: 19 NRTI-experienced: 10	NNRTI-naïve: 16 NNRTI-experienced: 3	-	-	-
CD4 (IQR) *Baseline*	402.5 (296-503.5)	83 (35-252)	160 (78-259)	<0.001	<0.001	NS
Follow-up	315 (221-472.8)	185 (81-312)	192 (98-255)	0.007	0.01	NS
VL (IQR) *Baseline*	4.6 (4.1-4.9)	5.2 (4.6-5.6)	4.6 (4.4-5.6)	0.002	NS	NS
Follow-up	4.8 (4.3-5)	4.4 (4.1-4.8)	4.8 (4.5-5)	NS	NS	NS
Months (IQR)[3]	12.5 (2-21.5)	20 (7-36)	39 (16.5-54.5)	0.04	0.01	0.04
Pol genetic distance (IQR)[4]	0.75% (0.44%-1.23%)	2.17% (1.6%-2.84%)	1.92% (1.47%-2.98%)	<0.001	<0.001	NS

Footnotes: [1]Wilcoxon Rank Sum Tests were used to compare all median values. Fisher's exact tests were used to compare proportions (e.g.,
proportion that were male). [2]In the M184V Group, 9 of the 10 individuals who were NRTI-experienced individuals at baseline had received a 3TC-
or FTC-containing regimen but none had developed M184V (or M184I) prior to initial sampling. In the NNRTI-resistance group, 6 of the 16
individuals who were NNRTI-naïve at baseline were completely ART-naïve; none of the 3 NNRTI-experienced individuals had previous NNRTI-
resistance mutations. [3]Months between the baseline and follow-up samples. [4]The percentage of nucleotides that differed between baseline and
follow-up in the HIV-1 *pol* sequence performed for clinical purposes at the time the samples were initially obtained. The *pol* sequence usually
encompassed the complete protease and the first 300 RT codons.

At the time the initial plasma samples were obtained, the individuals in the control group had a

higher median CD4 count (402.5 cells/mm^3) compared to those in the M184V (83 cells/mm^3) and NNRTI-

resistance (160 cells/mm^3) groups. At the time of follow-up sampling, the median CD4 count in the

control group decreased while the median CD4 count in the M184V and NNRTI groups increased (Table

1). The median time between the two samples differed between the three groups: 12.5 months for the

control group, 20 months for the M184V group, and 39 months for the NNRTI-resistance group. The

median uncorrected genetic distance in the protease and RT genes was 0.75% for the individuals in the

control group compared with 2.17% and 1.92% in the M184V and NNRTI-resistance groups, respectively.

Baseline sequences

The median number of reads per sample was 2883 (IQR: 1264 – 4981). Within each sample, the

coverage was highly uniform across positions 37-356. Across all samples, 98.4% of paired reads

encompassed ≥300 nucleotides. All of the sequences belonged to subtype B based on phylogenetic

analysis of the *pol* gene. Among the 80 baseline sequences, 87 (27.2%) positions had a nucleotide

difference from HXB2 present in ≥20% of sequence reads (Figure 1). At positions 47, 200, 201, 213, 227,

265, and 305 more than one-half of the nucleotides differed from HXB2 but were the same as the

subtype B consensus sequence.

Figure 1

HIV-1 5'-leader nucleotide differences from HXB2 observed in the 80 baseline sequences superimposed

on a diagram of its RNA secondary structure. Nucleotides observed in ≥20% of reads in more than 10

sequences are shown in orange; those present in fewer than 10 sequences are shown in purple.

Insertions and deletions are not shown. Positions 1 to 36 were not sequenced. TAR: trans-activation

response element (positions 1-57); PolyA: polyadenylation signal (positions 58-104); H1: helix 1 tertiary

structure; H2: helix 2 tertiary structure; PBS: primer binding site (positions 182-199); DIS: dimer

initiation site (positions 242-278); psi: packaging signal (positions 312-315). The Matrix initiation codon

is surrounded by a green box; it is base-paired to the U5 triplet. The primer activation signal nucleotides

are colored green, the C-rich region nucleotides are colored yellow, and the PBS nucleotides are colored

maroon.

The poly A motif (AATAAA; positions 73-78), primer activating signal (PAS; positions 125-130)

and primer binding site (PBS; positions 182-199) were completely conserved in the 80 baseline

sequences. The U5 region was represented by CGT (91% of sequences) or CAT (9% of sequences) each of

which maintained complementarity to the Matrix initiation codon (positions 336-338). The dimerization

signal (DIS; positions 257-262) was represented by GCGCGC in all but five sequences. The RNA packaging

signal (PSI; positions 312-325) contained the same nucleotides in all but three sequences.

Figure 2 shows that the distribution of nucleotides and indels was highly similar between the 80

baseline samples and the 1,417 samples downloaded from the LANL database (Supplementary Figure 1).

There were no apparent differences in the proportions of nucleotides or indels between the sequences

from the 56 individuals who were ART-naïve and the 24 individuals who were ART-experienced at

baseline (Supplementary Figure 2). Figure 3 shows that 52 positions had more than one nucleotide

detected in ≥20% of sequence reads. At positions 200, 201, 304, 224, and 354, more than 10% of

samples had a mixture of two nucleotides.

Figure 2

Distribution of HIV-1 5'-leader nucleotide differences from HXB2 and indels in the 80 baseline sequences

and in 1,417 one-per-person Los Alamos National Laboratory HIV Sequence Database (LANL) dataset.

Figure 3

HIV-1 5'-leader positions ranked according to the frequency with which they contained a mixture of two

or more nucleotides. Each nucleotide in a mixture was required to present in ≥20% of NGS reads.

Supplementary Figure 1

HIV-1 5-leader nucleotide differences from the HXB2 sequence observed in 1,417 sequences in

the Los Alamos National Laboratories HIV Sequence Database dataset. Superscripts indicate the

percentage of times that a nucleotide was reported. Highlighted regions include (1) TAR: trans-

activation response element; (2) PolyA: polyadenylation signal loop with a box surrounding the

poly A motif; (3) U5; (4) PAS: primer activation signal; (5) PBS: primer binding site; (6) DIS: dimer

initiation signal loop with a box surrounding the palindromic DIS; (7) major 5' splicing site; (8)

PSI packaging signal; (9) Matrix protein with a box surrounding the start codon.

<u>Supplementary Figure 2</u>

Distribution of HIV-1 5'-leader nucleotide differences from HXB2 and indels in the 56 baseline sequences

from ART-naïve individuals compared with the 24 baseline sequences from ART-experienced individuals.

Compared to HXB2, two individuals had large deletions. In one individual, positions 119 to 161

were deleted and in the other individual, positions 281 to 288 were deleted. Both of these deletions

were also present in the follow-up sequence from the same individual suggesting that these deletions

were not sequencing artifacts. An additional 42 baseline samples had deletions of 1 to 3 nucleotides.

The most frequent positions with deletions were between positions 301 to 303 (20 samples) and

between positions 150 to 153 (13 samples). Compared to HXB2, 54 samples had one or more insertions,

with the most frequent occurring between positions 300 to 305 (26 samples), 254 to 255 (6 samples),

165 to 167 (5 samples), and 198 to 202 (4 samples). Eight samples had insertions containing more than

three nucleotides.

Follow-up sequences

Figure 4 summarizes the number of individuals by the number of positions at which a ≥4-fold

change in the proportion of a nucleotide or indel occurred between baseline and follow-up for each of

the three sample groups. The median number of changes per individual was higher in the M184V (3;

IQR:1-4; p=0.014 Wilcoxon Rank Sum Test) and NNRTI groups (2; IQR: 1-4; p=0.12; Wilcoxon Rank Sum

Test) than in the control group (0.5; IQR:0-4). The three control group individuals with large changes

included one individual who may have experienced a re-infection as evidenced by a nucleotide distance

of 5.4% between their baseline and follow-up HIV-1 *pol* sequence.

Figure 4

Number of HIV-1 5'-leader positions at which a nucleotide or indel exhibited a ≥4-fold change in its

proportion between baseline and follow-up and which was present at a level of ≥20% at follow-up in

each of the three patient groups.

263   Fifty-three of the 63 deletions found in either baseline or follow-up samples were present at

264 both time points. Fifty-three of the 70 insertions present in either baseline or follow-up samples were

265 present at both time points. A neighbor-joining phylogenetic tree using the Jaccard distance to weight

266 the distance between overlapping IUPAC nucleotides is shown in Figure 5.

268 <u>Figure 5</u>

269 Neighbor-joining tree containing the 80 baseline and follow-up sequences from this study.

270 Sample IDs for the M184V group are colored blue; those for the NNRTI group are colored

271 yellow; and those for the Control group are colored red. Bootstrap values are indicated at each

272 node of the tree.

Figure 6A shows the positions at which at least one nucleotide changed its proportion by ≥4-fold

and which occurred in ≥20% of sequence reads. The positions at which nucleotide changes occurred

most frequently are shown in Figure 6B. Positions 200 and 201, which were the positions most likely to

have mixtures at baseline, were also the positions most likely to exhibit a ≥4-fold change in the

proportion of a nucleotide. Position 201 was significantly more likely to exhibit a ≥4-fold change in its

proportions in the M184V (9/29 vs. 0/32; p=0.0006; Fisher's Exact Test) and the NNRTI-resistance groups

(4/19 vs. 0/32; p=0.02; Fisher's Exact Test) compared with the control group. There were no significant

differences between each of the three groups at any other position including position 200. At position

201, all four nucleotides were present at baseline and there was no predilection for any particular

change between baseline and follow-up.

<u>Figure 6</u>

Distribution of positions at which a nucleotide or indel changed its prevalence by ≥4-fold

according to patient group (A) and a table indicating the ten positions that changed most often

(B).

<u>**Distribution of mixtures in previously published clonal sequences and in NGS**</u>

The five publications describing a minimum of three clones per individual from at least five

individuals reported a total of 294 sequences from 42 individuals. At five positions, ≥10% of individuals

had a mixture of ≥2 nucleotides in different clones including positions 200 (n=16 individuals; 38.1%), 201

(n=11 individuals; 26.2%), 305 (n=7 individuals; 16.7%), 152 (n=5 individuals; 11.9%), and 281 (n=5

individuals; 11.9%).

The six publications in the NCBI SRA describing 5'-leader sequences from 295 individuals

reported that the most common positions containing a mixture at least two nucleotides (i.e., each

present in ≥20% of NGS reads) were also positions 200 (n=103 individuals; 34.9%) and 201 (n=62

individuals; 21.1%). Table 2 illustrates the 15 positions that most frequently contained mixtures in this

study and the frequency with which these positions contained mixtures in the GenBank and NCBI SRA

datasets. In contrast to the 5'-leader, among 384 RT sequences from 379 individuals in the same six

NCBI   SRA   dataset   publications,   no   position   had   a   mixture   in   ≥6%   of   positions.

Table 2. Proportion of HIV-1 5'-Leader Positions Containing a Mixture of Nucleotides in Sampled Viruses in this Study, in Previously Published
Studies in GenBank, and in NGS Studies in the NCBI Sequence Read Archive (SRA)
305

Position	Baseline Samples from this Study (n=80 individuals)[1]	Published Studies of Individuals with Multiple Clones (GenBank) (n=42 individuals)[2]	Published Studies of Individuals Undergoing NGS (NCBI SRA) (n=295 individuals)[3]
200	45.0%	38.1%	34.9%
201	28.8%	26.2%	21.1%
304	15.0%	4.8%	4.1%
224	10.0%	9.5%	6.1%
354	10.0%	2.4%	1.4%
305	8.8%	16.7%	6.0%
152	7.5%	11.9%	6.8%
286	6.3%	9.5%	5.8%
96	6.3%	6.9%	8.2%
263	6.3%	2.4%	2.7%
281	5.0%	11.9%	1.5%
47	5.0%	4.8%	8.2%
215	5.0%	7.1%	2.5%
227	5.0%	4.8%	2.7%
353	5.0%	2.4%	1.0%

306
Footnote: [1]A position was considered to have a mixture if at least one non-consensus nucleotide was present in ≥20% of reads. [2]Data were
obtained from five publications reporting ≥3 clones per individual from ≥5 individuals. A total of 294 sequences were performed (i.e., a mean of
7 clones per individual). A position was considered to have a mixture if at least one clone had a non-consensus nucleotide. Thirty-one individuals
(74%) had subtype B viruses and 11 patients had subtype C viruses. [3]A position was considered to have a mixture if at least one non-consensus
nucleotide was present in ≥20% of reads. Sixty-four percent of sequences belonged to subtype C; 21% to subtype B; and 15% to other subtypes
or circulating recombinant forms.

<u>DISCUSSION</u>

To our knowledge, this is the first study of paired HIV-1 5'-leader sequences from individuals

who did or did not develop RT-associated DRMs. Contrary to our initial hypothesis, we did not observe

co-evolutionary changes between RT and 5'-leader sequences. The only 5'-leader position (position 201)

that demonstrated a higher likelihood of evolution in samples from individuals who developed RT-

associated DRMs is one of the most variable 5'-leader positions. However, our study uncovered a

previously unreported phenomenon, wherein specific 5'-leader positions, particularly positions 200 and

201, exhibited an extraordinarily high likelihood of containing two or more nucleotides each in more

than 20% of NGS reads. We corroborated this finding by analyzing two previously published datasets:

five published studies of clonal dideoxy-terminator Sanger sequences and six NCBI SRA NGS datasets

encompassing the HIV-1 5'-leader.

Although HIV-1 is a quasispecies characterized by the presence of multiple circulating variants,

the markedly high prevalence of nucleotide mixtures at two particular positions is striking. The

prevalence of mixtures in our 80 baseline sequences was 45% for position 200 and 29% for position 201.

In our analysis of previously published clonal sequences, these prevalences were 38% and 26%,

respectively, and in our analysis of previously published NGS data, these prevalences were 35% and

21%, respectively. Moreover, in these analyses, positions 200 and 201 contained mixtures at a

frequency several times higher than that observed at any other 5'-leader position or, in the NCBI SRA

NGS dataset, at any RT position. The fact that the previously published clonal and NGS datasets

contained large numbers of non-subtype B isolates suggests that the propensity of positions 200 and

201 to contain nucleotide mixtures is not limited to one subtype.

Positions 200 and 201 are immediately downstream of the PBS, situated opposite to the

consecutive A nucleotides at tRNA positions 58 and 57, respectively (3). The significance of

complementarity between the 5'-leader and tRNA at these two positions, however, has not been

studied. We believe that the most plausible explanation for the high proportion of mixtures at these two

positions may be that they are particularly error prone as they represent the first two nucleotides added

following the second strand transfer step during the process of HIV-1 reverse transcription (5).

Our study is limited because we performed NGS without using unique molecular identifiers

(UMIs) (22). The use of UMIs would have allowed us to precisely quantify each variant within the HIV-1

quasispecies and to thus reliably identify linkages between positions in the same variant (22). Our study

is also limited because we studied convenience samples and did not have information on the duration of

infection of the individuals in our study. If a high proportion of mixtures at positions 200 and 201 can be

found in recently infected individuals this would support the hypothesis that these two positions are

highly error-prone. In contrast, if the mixtures at these positions develops during the course of HIV-1

infection, the possibility that mixtures at these positions contribute to viral replication fitness may be

more likely.

<u>Acknowledgements</u>

JN and RWS have been funded in part by an NIH grant R03 AI147632. EVP, JDP and MK have been

funded in part by an NIH grant U54 AI170856.

<u>Conflicts of interest</u>

The author(s) declare that there are no conflicts of interest.

358
REFERENCES

1. Berkhout B. Structure and Function of the Human Immunodeficiency Virus Leader RNA. In: Cohn
WE, Moldave K, editors. Progress in Nucleic Acid Research and Molecular Biology [Internet].
Academic Press; 1996 [cited 2021 Oct 5]. p. 1–34. Available from:
https://www.sciencedirect.com/science/article/pii/S0079660308603591

2. Keane SC, Summers MF. NMR Studies of the Structure and Function of the HIV-1 5'-Leader. Viruses.
2016 21;8(12).

3. Larsen KP, Mathiharan YK, Kappel K, Coey AT, Chen DH, Barrero D, et al. Architecture of an HIV-1
reverse transcriptase initiation complex. Nature. 2018;557(7703):118–22.

4. Ha B, Larsen KP, Zhang J, Fu Z, Montabana E, Jackson LN, et al. High-resolution view of HIV-1 reverse
transcriptase initiation complexes and inhibition by NNRTI drugs. Nat Commun. 2021 May
4;12(1):2500.

5. Krupkin M, Jackson LN, Ha B, Puglisi EV. Advances in understanding the initiation of HIV-1 reverse
transcription. Curr Opin Struct Biol. 2020 Dec 1;65:175–83.

6. Chen S, Zhou Y, Chen Y, Gu J. fastp: an ultra-fast all-in-one FASTQ preprocessor. Bioinformatics.
2018 Sep 1;34(17):i884–90.

7. Li H. Minimap2: pairwise alignment for nucleotide sequences. Bioinformatics. 2018 Sep
15;34(18):3094–100.

8. Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, Homer N, et al. The Sequence Alignment/Map
format and SAMtools. Bioinformatics. 2009 Aug 15;25(16):2078–9.

9. Rice P, Longden I, Bleasby A. EMBOSS: The European Molecular Biology Open Software Suite. Trends
Genet. 2000 Jun 1;16(6):276–7.

10. Katoh K, Frith MC. Adding unaligned sequences into an existing alignment using MAFFT and LAST.
Bioinformatics. 2012 Dec 1;28(23):3144–6.

11. Novitsky VA, Montano MA, McLane MF, Renjifo B, Vannberg F, Foley BT, et al. Molecular Cloning
and Phylogenetic Analysis of Human Immunodeficiency Virus Type 1 Subtype C: a Set of 23 Full-
Length Clones from Botswana. J Virol. 1999 May;73(5):4427–32.

12. Rolland M, Tovanabutra S, deCamp AC, Frahm N, Gilbert PB, Sanders-Buell E, et al. Genetic impact
of vaccination on breakthrough HIV-1 sequences from the STEP trial. Nat Med. 2011 Mar;17(3):366–
71.

13. Ochsenbauer C, Edmonds TG, Ding H, Keele BF, Decker J, Salazar MG, et al. Generation of
Transmitted/Founder HIV-1 Infectious Molecular Clones and Characterization of Their Replication
Capacity in CD4 T Lymphocytes and Monocyte-Derived Macrophages. J Virol. 2012 Mar
1;86(5):2715–28.

14. Parrish NF, Gao F, Li H, Giorgi EE, Barbian HJ, Parrish EH, et al. Phenotypic properties of transmitted
founder HIV-1. Proc Natl Acad Sci U S A. 2013 Apr 23;110(17):6626–33.

15. Gondim MVP, Sherrill-Mix S, Bibollet-Ruche F, Russell RM, Trimboli S, Smith AG, et al. Heightened
resistance to host type 1 interferons characterizes HIV-1 at transmission and after antiretroviral
therapy interruption. Sci Transl Med. 2021 Jan 13;13(576):eabd8179.

16. Gall A, Ferns B, Morris C, Watson S, Cotten M, Robinson M, et al. Universal Amplification, Next-
Generation Sequencing, and Assembly of HIV-1 Genomes. J Clin Microbiol. 2012 Dec;50(12):3838–
44.

17. Illingworth CJR, Roy S, Beale MA, Tutill H, Williams R, Breuer J. On the effective depth of viral
sequence data. Virus Evol. 2017 Nov 14;3(2):vex030.

18. Fedonin GG, Fantin YS, Favorov AV, Shipulin GA, Neverov AD. VirGenA: a reference-based assembler
for variable viral genomes. Brief Bioinform. 2019 Jan 18;20(1):15–25.

19. Vilsker M, Moosa Y, Nooij S, Fonseca V, Ghysens Y, Dumon K, et al. Genome Detective: an
automated system for virus identification from high-throughput sequencing data. Bioinformatics.
2019 Mar 1;35(5):871–3.

20. Zhang Y, Wymant C, Laeyendecker O, Grabowski MK, Hall M, Hudelson S, et al. Evaluation of
Phylogenetic Methods for Inferring the Direction of Human Immunodeficiency Virus (HIV)
Transmission: HIV Prevention Trials Network (HPTN) 052. Clin Infect Dis Off Publ Infect Dis Soc Am.
2020 Feb 7;72(1):30–7.

21. Ye L, Gribling-Burrer AS, Bohn P, Kibe A, Börtlein C, Ambi UB, et al. Short- and long-range
interactions in the HIV-1 5ʹ UTR regulate genome dimerization and packaging. Nat Struct Mol Biol.
2022 Apr;29(4):306–19.

22. Zhou S, Hill CS, Spielvogel E, Clark MU, Hudgens MG, Swanstrom R. Unique Molecular Identifiers and
Multiplexing Amplicons Maximize the Utility of Deep Sequencing To Critically Assess Population
Diversity in RNA Viruses. ACS Infect Dis. 2022 Dec 9;8(12):2505–14.

0.005

A

B

Top 10 positions

Position	Control (n=32)	M184V (n=29)	NNRTI (n=19)
200	9% (3)	31% (9)	26% (5)
201	0% (0)	31% (9)	21% (4)
152	3% (1)	14% (4)	5% (1)
305	9% (3)	10% (3)	5% (1)
96	6% (2)	10% (3)	5% (1)
227	3% (1)	10% (3)	5% (1)
354	3% (1)	10% (3)	5% (1)
265	16% (5)	7% (2)	16% (3)
263	12% (4)	7% (2)	16% (3)
47	6% (2)	7% (2)	16% (3)